United States Drug Patent 10,570,453: Claim Scope, Iloperidone Exclusivity, and Patent Landscape
U.S. Patent No. 10,570,453 protects a pharmacogenomic dosing method for iloperidone based on the rs993648 genotype in the CERKL gene. The patent distinguishes patients with the AG genotype, who qualify for a higher iloperidone dose, from patients with non-AG genotypes, who receive a lower dose because of an alleged increased risk of QT prolongation. The principal commercial value is a method-of-use position around individualized dosing, not composition-of-matter protection for iloperidone.
The independent claim requires five central elements: a human biological specimen, characterization of a CERKL expression product or associated genotype, classification of rs993648 as AG or non-AG, administration of iloperidone or a covered metabolite or salt, and genotype-dependent dosing.
What does U.S. Patent 10,570,453 protect?
The patent protects a treatment decision that links CERKL rs993648 genotype to iloperidone dose selection.
| Claim element |
Required limitation |
| Patient |
A human individual |
| Sample |
A biological specimen obtained from that individual |
| Biomarker |
CERKL gene expression product, with the claim expressly identifying rs993648 |
| Lower-risk genotype |
AG at rs993648 |
| Higher-risk genotypes |
Non-AG, which ordinarily encompasses AA and GG |
| Drug |
Iloperidone, an iloperidone metabolite, or a pharmaceutically acceptable salt |
| Higher dose branch |
A first quantity |
| Lower dose branch |
A second quantity less than the first |
| Dependent dose |
Claim 2 specifies 24 mg/day for the first quantity |
| Reduced dose |
Claim 3 requires less than 24 mg/day |
| Disease population |
Claim 4 adds long QT syndrome |
| Additional biomarker |
Claim 5 adds CYP2D6 genotype determination |
Claim 1 is a conditional treatment algorithm. It does not require a particular assay platform, specimen type, laboratory method, route of administration, or commercial formulation. The claim therefore reaches laboratory-directed prescribing decisions across a range of testing formats.
The claim does not expressly require a schizophrenia diagnosis. It also does not require that the physician administer a specific Fanapt tablet strength. Its text covers iloperidone broadly, along with an iloperidone metabolite and pharmaceutically acceptable salts.
How does claim 1 operate?
Claim 1 establishes two treatment branches:
- If rs993648 is AG, the patient is classified as not having an increased risk of QT prolongation and receives the first quantity.
- If rs993648 is non-AG, the patient is classified as having an increased risk and receives a second quantity that is lower than the first.
The claim language supplied identifies AG as the favorable genotype. “Non-AG” is broader than a single alternative genotype. For a biallelic A/G SNP, it would ordinarily include AA and GG, subject to the patent’s specification and the applicable interpretation of the claim.
The claim does not state that the second dose must be a particular number. Claim 3 confirms only that it is less than 24 mg/day when claim 2 supplies 24 mg/day as the first quantity.
This structure creates a potentially important distinction:
- A regimen of 24 mg/day for AG patients falls within claims 1 and 2 if the other limitations are met.
- A lower dose for non-AG patients falls within claims 1 and 3 if the other limitations are met.
- A fixed dose of 24 mg/day for all patients would not satisfy the genotype-dependent dose limitation.
- A lower dose for every patient may avoid the literal two-branch dosing structure, depending on the facts and the interpretation of the claim.
What is the scope of claims 2 through 5?
Claim 2: 24 mg/day for the first quantity
Claim 2 narrows claim 1 by specifying that the first quantity is 24 mg/day. The claim is commercially relevant because 24 mg/day is the maximum total daily dose identified in the FDA-approved Fanapt prescribing framework for many adult patients, subject to titration and dose-adjustment considerations.
A practice that administers 24 mg/day to an AG patient after testing the CERKL rs993648 genotype is the clearest target for claim 2.
Claim 3: less than 24 mg/day for the second quantity
Claim 3 covers the non-AG branch when the selected dose is below 24 mg/day. It does not identify a lower boundary. A dose of 23 mg/day, 12 mg/day, 6 mg/day, or another lower quantity could fall within the literal numerical limitation, assuming the remaining limitations are satisfied.
The claim does not require that the lower dose be selected because of CYP2D6 status. CYP2D6 appears only in dependent claim 5.
Claim 4: patients with long QT syndrome
Claim 4 narrows the method to individuals suffering from long QT syndrome, or LQTS. This substantially reduces the patient population but may increase the claim’s clinical specificity.
The claim should be read together with the specification and prosecution history to determine whether “long QT syndrome” refers only to congenital LQTS or also encompasses acquired QT-prolongation conditions. The claim text alone does not resolve that issue.
Claim 5: CYP2D6 testing
Claim 5 requires determining the individual’s CYP2D6 genotype in addition to the CERKL-related analysis. It does not specify a CYP2D6 allele, metabolizer classification, or dosing consequence.
The claim therefore covers a workflow in which both CERKL rs993648 and CYP2D6 are determined, even if the CYP2D6 result is not expressly used to select the dose. Whether a court would require a meaningful therapeutic role for the CYP2D6 result would depend on claim construction and the surrounding specification.
What are the principal infringement issues?
Direct infringement would generally require performance of every limitation of a claim. For claim 1, the relevant conduct would include:
- obtaining or using a specimen from a human patient;
- characterizing the CERKL-related biomarker;
- classifying rs993648 as AG or non-AG;
- administering iloperidone, a covered metabolite, or a salt;
- selecting a higher dose for AG and a lower dose for non-AG.
The “characterizing, or having characterized” language expands the potential actor set. A physician, hospital, testing laboratory, specialty pharmacy, or other participant may perform different portions of the workflow. That does not automatically establish infringement. Divided-infringement questions would depend on direction, control, joint activity, contractual relationships, and the facts of the implementation.
A diagnostic laboratory that reports only the rs993648 genotype may not itself administer iloperidone. Conversely, a prescriber may rely on a test performed by another entity. The allocation of the testing and treatment steps is therefore central to enforcement risk.
The claim also presents an evidentiary issue: the patent requires a genotype-linked risk classification. A party administering a low dose to a non-AG patient could argue that the dose was chosen for another reason, such as renal function, tolerability, CYP2D6 status, drug interactions, or general clinical judgment. The strength of that defense would depend on the claim’s construction and the treatment records.
What formulation and manufacturing protection does the patent provide?
U.S. Patent 10,570,453 does not, based on the supplied claims, claim:
- a particular tablet formulation;
- a controlled-release formulation;
- an injectable or transdermal delivery system;
- a specific excipient;
- a manufacturing process;
- a crystalline or polymorphic form;
- a salt-selection process;
- a pharmaceutical composition as such.
Its formulation coverage is indirect. A commercial product can be used in the claimed method if it contains iloperidone or another covered form and is administered according to the genotype-dependent dosing algorithm.
This distinction matters for generic entry. A generic manufacturer may be able to manufacture and sell iloperidone without practicing every step of the patented method. Risk increases if the generic label, prescribing information, promotional material, electronic ordering system, or testing partnership encourages the CERKL-guided dosing method.
What is the FDA and Orange Book significance?
Iloperidone is an FDA-approved small-molecule antipsychotic marketed as Fanapt. The FDA-approved labeling identifies QT-prolongation risk and contains clinical dosing and dose-adjustment information. The label also addresses pharmacokinetic considerations involving CYP2D6 and drug interactions. It does not follow from the supplied patent claims that the FDA label requires CERKL rs993648 testing or implements the claimed AG/non-AG dosing algorithm (FDA, 2024).
An Orange Book listing would matter because a listed patent can support a patent certification requirement in an abbreviated new drug application. A method-of-use patent may be listed only if it meets FDA listing requirements and the listed method corresponds to an approved use.
The patent number alone does not establish:
- that U.S. Patent 10,570,453 is listed in the Orange Book;
- the listed patent use code;
- whether the patent is delisted;
- whether it is subject to a terminal disclaimer;
- whether an ANDA applicant has filed a Paragraph IV certification.
Those facts are controlled by FDA Orange Book records, patent prosecution records, and litigation dockets rather than by the claim text.
When does U.S. Patent 10,570,453 lose exclusivity?
The patent issued on February 25, 2020. The expiration date cannot be determined from the claims alone. For a utility patent, the ordinary term is generally 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and any relevant priority or continuation history (35 U.S.C. §§ 154, 156).
The following data control the effective expiry:
| Term issue |
Commercial relevance |
| Earliest effective nonprovisional filing date |
Establishes the basic 20-year term |
| Patent-term adjustment |
May extend the term for USPTO delay |
| Patent-term extension |
Could apply for qualifying regulatory delay, although method-of-treatment patents require separate analysis |
| Terminal disclaimer |
May tie expiry to another patent |
| Continuation status |
Can affect priority and term calculations |
| Maintenance fees |
Nonpayment can cause expiration before the statutory term |
The grant date is not the expiry date. A reliable freedom-to-operate conclusion requires the patent’s continuity data, USPTO term calculation, and maintenance-fee status.
What Paragraph IV and generic-entry risks exist?
This is a small-molecule product, so the relevant abbreviated pathway is an ANDA, not a biosimilar application. The principal generic strategies are:
| Generic strategy |
Potential effect of the '453 patent |
| Paragraph III certification |
Delays approval until patent expiry |
| Paragraph IV certification |
Creates possible patent litigation and a 30-month stay if statutory conditions are met |
| Section viii carve-out |
Removes a patented method from the label if FDA accepts the carve-out |
| Non-infringement position |
Argues that the generic label does not direct CERKL-based dosing |
| Invalidity position |
Challenges written description, enablement, anticipation, obviousness, or indefiniteness |
| Label-neutral launch |
Avoids express promotion of the patented genotype algorithm, subject to induced-infringement risk |
The patent is narrower than a compound patent but may be harder to design around if the generic label or clinical support materials expressly recommend CERKL testing and genotype-dependent dosing.
A generic could seek approval for iloperidone without including the patented pharmacogenomic use. The commercial value of a carve-out depends on whether the carved-out use is material to prescribing and whether the remaining label still supports broad substitution.
How strong is the patent estate?
The '453 patent has several strengths:
- It identifies a specific genetic locus.
- It links the genotype to a concrete dosing decision.
- It covers both the favorable AG genotype and the non-AG category.
- Claim 2 aligns the higher-dose branch with 24 mg/day.
- The claims do not depend on a particular commercial test kit.
The principal vulnerabilities are:
- potential enablement and written-description challenges concerning the breadth of “CERKL expression product” and “non-AG”;
- potential ambiguity between expression-product characterization and direct genotype determination;
- prior-art challenges involving pharmacogenomic dosing, QT-risk stratification, CYP2D6 testing, and iloperidone dosing;
- questions concerning whether the asserted genotype-dosing relationship was adequately supported as of the filing date;
- enforcement difficulty when testing and prescribing are performed by separate entities;
- possible label carve-out strategies by generic applicants.
The patent is therefore a targeted method-of-use asset. It does not block all iloperidone manufacturing, sale, or prescribing. Its strongest position is against a coordinated service that tests rs993648 and directs 24 mg/day for AG patients and less than 24 mg/day for non-AG patients.
What patent litigation and settlement issues matter?
A complete litigation assessment requires the USPTO Patent Center, FDA Orange Book, PACER, and relevant district-court and Federal Circuit records. The claim text does not establish whether:
- a Paragraph IV notice has been served;
- the patent has been asserted against an ANDA applicant;
- a 30-month stay has been triggered;
- the patent has been invalidated or narrowed;
- a settlement agreement restricts generic launch;
- a covenant not to sue or license affects enforcement.
For transaction diligence, the critical documents are the patent’s prosecution history, any Orange Book listing, ANDA notice letters, complaints, claim-construction orders, settlement terms, and final judgments.
How does the '453 patent compare with conventional iloperidone patents?
| Protection type |
Typical subject matter |
Relevance to the '453 patent |
| Composition of matter |
Iloperidone molecule or broad chemical class |
Usually broader and earlier, but may have expired or approach expiry |
| Formulation |
Tablet, release profile, excipient, dosage form |
Protects product construction rather than patient selection |
| Manufacturing |
Synthesis, purification, crystalline form |
Can restrict supply-chain workarounds |
| Method of treatment |
Disease treatment or dose regimen |
Covers clinical use |
| Pharmacogenomic method |
Biomarker-linked treatment selection |
The principal category of the '453 patent |
| Regulatory exclusivity |
FDA statutory exclusivity |
Separate from patent rights and not established by the patent number |
The '453 patent should be analyzed as one layer in the iloperidone estate. It does not replace composition, formulation, process, or regulatory exclusivity analysis.
Key Takeaways
- U.S. Patent 10,570,453 claims genotype-guided iloperidone dosing based on CERKL rs993648.
- AG patients are assigned the higher dose branch; non-AG patients are assigned a lower dose branch.
- Claim 2 specifies 24 mg/day for the higher-dose branch.
- Claim 3 covers less than 24 mg/day for the lower-dose branch.
- Claim 4 narrows the method to patients with LQTS.
- Claim 5 requires additional CYP2D6 genotype determination.
- The patent does not claim iloperidone as a molecule, a tablet formulation, or a manufacturing process.
- Generic exposure will depend heavily on the approved label, any Orange Book listing, Paragraph IV certifications, and the ability to carve out the pharmacogenomic method.
- The patent’s practical value is highest where one integrated service performs testing and directs genotype-specific iloperidone dosing.
- The patent’s exact expiry date cannot be determined from the claim text or grant date alone.
FAQs
Does the patent require a CERKL genetic test?
The claim requires characterization of a CERKL-related expression product and expressly identifies the rs993648 genotype. A test that determines rs993648 would be the most direct implementation, although the precise acceptable characterization method depends on the specification and claim construction.
Does a generic iloperidone tablet infringe the patent by itself?
No. The claims supplied are method claims. A tablet does not by itself practice the claimed genotype-testing and dose-selection steps. Risk may arise from labeling, instructions, promotional activity, or coordinated testing and prescribing.
Does claim 4 cover all patients at risk of QT prolongation?
No. Claim 4 narrows the method to an individual suffering from LQTS. Claim 1 is broader in patient population but still requires the specified CERKL genotype classification and dose branching.
Can a physician avoid the patent by testing CYP2D6 instead of CERKL?
Testing CYP2D6 alone would not satisfy the CERKL limitation in claim 1. Claim 5 requires CYP2D6 determination in addition to the CERKL-related characterization.
Is this patent a biosimilar barrier?
No. Iloperidone is a small molecule. The relevant competitive pathway is generic approval through an ANDA, with Paragraph IV and Section viii strategies potentially affecting the patented method.
References
-
Food and Drug Administration. (2024). Fanapt (iloperidone) prescribing information. U.S. Department of Health and Human Services.
-
U.S. Patent and Trademark Office. (2020). U.S. Patent No. 10,570,453. Washington, DC: U.S. Department of Commerce.
-
U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term provisions under 35 U.S.C. §§ 154 and 156. Washington, DC: U.S. Department of Commerce.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
35 U.S.C. §§ 154, 156, 271, 282.
